Emerging drugs targeting PD-1 and PD-L1: Reality or hope?

Expert Opinion on Emerging Drugs

Volumn 19, Issue 4, 2014, Pages 557-569

  Casaluce, Francesca ^a   Sgambato, Assunta ^a   Sacco, Paola Claudia ^b   Palazzolo, Giovanni ^c   Maione, Paolo ^b   Rossi, Antonio ^b   Ciardiello, Fortunato ^a   Gridelli, Cesare ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c Division of Radiation Oncology   (Italy)

Author keywords

Anti programmed cell death protein agents; Anti programmed death ligand 1 agents; Immune checkpoints; Nivolumab; NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BMS 936559; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

CANCER THERAPY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; LUNG CANCER; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DESIGN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84912094256     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.964682     Document Type: Review

References (79)

1. GLOBOCAN 2012: lung cancer, estimated incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
3. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology (NCCN Guideliness). Nonsmall cell lung cancer. Version 3. 2014. Available from: http://www.nccn.com [Accessed 26 May 2014]
4. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5(9):1416-23
5. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
7. Yang JC, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, Phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012;32:abstract #LBA7500
8. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(25):2385-94
9. Pfizer reports positive phase 3 study outcome Of XALKORI (crizotinib) compared to chemotherapy in previously untreated patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Available from: http://www. pfizer.com/news/press-release/[Last accessed 26 May 2014]
10. Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012;12:923-37
11. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
12. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7
13. Ramnath N, Tan D, Li Q, et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2006;55(8):891-9
14. Bremnes RM, Al-Shibli K, Donnem T, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2011;6:824-33
15. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-17
16. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-80
17. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-7
18. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-72
19. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
20. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166-82
21. Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28(3):682-8
22. Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7:567-73
23. Wölfle SJ, Strebovsky J, Bartz H, et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011;41(2):413-24
24. Hirahara K, Ghoreschi K, Yang XP, et al. Interleukin-27 priming of Tcells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012;36(6):1017-30
25. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63
26. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54
27. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
28. Bristol-Myers Squibb. Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. Available from: http://clinicaltrials.gov/show/NCT01285609 NLM identifier: NCT01285609 [Accessed 10 June 2014]
29. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-80
30. Selby M, Engelhardt J, Lu L-S, et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol 2013;31(Suppl):abstract 3061
31. Brahmer JR, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. Abstr. MO18.03 Available from: https://www.webges.com/cview/library/wclc/home
32. Study of Nivolumab (BMS-936558) in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012)-NCT01454102. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
33. Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. J Clin Oncol 2014;32(5 Suppl):abstract 8112
34. Antonia SJ, Brahmer JR, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8113
35. Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol 2014;32(5 Suppl):abstract 8023
36. Rizvi NA, Chow LQM, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol 2014;32(5 Suppl):abstract 8022
37. Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 2014;32(5 Suppl):abstract 8024
38. Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017)-NCT01642004. Available from: http:/https://clinicaltrials. gov/Last accessed 12 June 2014]
39. Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC (CheckMate 057)-NCT01673867. Available from: http:/https://clinicaltrials. gov/[Last accessed 3 July 2014]
40. An open-label, randomized, phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (CheckMate 026)-NCT02041533. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
41. A Safety Trial of Nivolumab (BMS-936558) in subjects with advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior systemic regimen (CheckMate 153)-NCT02066636. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
42. Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990/MK-3475-001/KEYNOTE-001)-NCT01295827. Available from: http:/https://clinicaltrials. gov/[Last accessed 3 July 2014]
43. Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8020
44. Gandhi L, Balmanoukian A, Hui R, et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression [abstract CT105]. Presented at AACR Annual Meeting, San Diego, 2014
45. Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8007
46. Study of two doses of MK-3475 (Pembrolizumab) versus docetaxel in previously-treated participants with non-small cell lung cancer (MK-3475-010/KEYNOTE-010)-NCT01905657. Available from: http:/https://clinicaltrials. gov/[Last accessed 3 July 2014]
47. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
48. A Phase 1 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with locally advanced or metastatic solid tumors-NCT01375842. Available from: http:/https://clinicaltrials. gov/[Last accessed 3 July 2014]
49. Horn L, Herbst RS, Spigel DR, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). Abstract MO18.01 Available from: https://www.webges.com/cview/library/wclc/home [Accessed 2 December 2013]
50. A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with PD-L1 positive locally advanced or metastatic non-small cell lung cancer-"FIR"-NCT01846416. Available from: http:/https://clinicaltrials. gov/[Last accessed 3 July 2014]
51. A randomized phase 2 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy-"POPLAR"-NCT01903993. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
52. A Phase 2 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with pd-l1 positive locally advanced or metastatic non-small cell lung cancer-"BIRCH"-NCT02031458. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
53. A randomized phase 3 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) compared to docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy-"OAK"-NCT02008227. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
54. A Phase 1 study to evaluate MEDI4736-NCT01693562. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
55. Brahmer JR, Rizvi NA, Lutzky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol 2014;32(5 Suppl):abstract 8021
56. A Phase 1b Study of MEDI4736 in combination with tremelimumab in subjects with advanced non-small cell lung cancer (D4190C00006)-NCT02000947. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
57. Pinder MC, Rizvi NA, Goldberg SB, et al. A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer. J Clin Oncol 2014;32(Suppl):abstract e19137
58. Safety study of IL-21/Anti-PD-1 combination in the treatment of solid tumors-NCT01629758. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
59. A Phase I study of an Anti-KIR antibody in combination with an anti-PD1 antibody in patients with advanced solid tumors-NCT01714739. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
60. Brahmer JL. PD-1/PD.L1 blockade for the treatment of NSCLC. Presentation MO9.2; IASCL WCLC 2013. Available from: https://www.webges.com/cview/library/wclc/home [Accessed 2 December 2013]
61. Villaruz LC, Kalyan A, Zarour H, et al. Immunotherapy in lung cancer. Transl Lung Cancer Res 2014;3(1):2-14
62. Phase II Anti-PD1 epigenetic priming study in NSCLC. (NA-00084192)-NCT01928576. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
63. Study of Nivolumab (BMS-936558) in subjects with advanced or metastatic squamous cell non-small cell lung cancer who have received at least two prior systemic regimens (CheckMate 063)-NCT01721759. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
64. Study of pembrolizumab (MK-3475) monotherapy in participants with advanced solid tumors and pembrolizumab combination therapy in participants with advanced non-small cell lung cancer (MK-3475-011/KEYNOTE-011)-NCT01840579. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
65. Study of pembrolizumab (MK-3475) in participants with advanced non-small cell lung cancer (MK-3475-025/KEYNOTE-025)-NCT02007070. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
66. A study of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with lung cancer (MK-3475-021/KEYNOTE-021)-NCT02039674. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
67. MK-3475 in melanoma and NSCLC patients with brain metastases-NCT02085070. Available from: http://clinicaltrials.gov/show/NCT02085070
68. Study of pembrolizumab (MK-3475) compared to platinum-based chemotherapies in participants with metastatic non-small cell lung cancer (MK-3475-024/KEYNOTE-024)-NCT02142738. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
69. Study to assess the safety, tolerability, and pharmacokinetics of amp-224 in patients with advanced cancer-NCT01352884. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
70. A Phase 1 study to evaluate AMP-514. Available from: http:/https://clinicaltrials. gov/[Last accessed 3 July 2014]
71. A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in combination with tarceva in patients with non-small cell lung cancer-NCT02013219. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
72. A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in combination with cobimetinib in patients with locally advanced or metastatic solid tumors-NCT01988896. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
73. MEDI4736 (Anti PD-L1) combined with gefitinib in subjects with non-small cell lung cancer (NSCLC)-NCT02088112. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
74. A global study to assess the effects of MEDI4736 in patients with locally advanced or metastatic non small cell lung cancer (ATLANTIC)-NCT02087423. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
75. Immune-modulated study of selected small molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st immune-mediated therapy (IMT; Tremelimumab) With a sequential switch to a 2nd IMT (MEDI4736) in patients with locally advanced or metastatic non-small-cell lung cancer-NCT02179671. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
76. Lung-MAP: S1400 biomarker-targeted second-line therapy in treating patients with recurrent stage IIIB-IV non-small cell lung cancer-NCT02154490. Available from: http:/https://clinicaltrials. gov/[Last accessed 3 July 2014]
77. A global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with stage iii unresectable non-small cell lung cancer (PACIFIC)-NCT02125461. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
78. MSB0010718C in solid tumors-NCT01772004. Available from: http:/https://clinicaltrials.gov/[Last accessed 3 July 2014]
79. Heery CR, O'Sullivan Coyne GH, Madan RA, et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J Clin Oncol 2014;32(5 Suppl): abstract 3064